Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to meet outsized demand.

Eli Lilly , which has added more than $300 billion in market value this year, largely on the back of investment optimism for its weight loss treatments, saw its two flagship produ

The S&P 500 slipped 0.3 percent after drifting between small gains and losses several times, though it's still near its all-time high set earlier this month. The Dow Jones Industrial Average edged down 0.2 percent, while the Nasdaq composite slipped 0.6 percent from its own record set the day before.